Somatropin + 0.09% Saline Solution
Phase 2/3Completed 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Burns
Conditions
Burns, Growth Hormone Treatment
Trial Timeline
Nov 1, 2015 → Nov 30, 2021
NCT ID
NCT03038594About Somatropin + 0.09% Saline Solution
Somatropin + 0.09% Saline Solution is a phase 2/3 stage product being developed by Pfizer for Burns. The current trial status is completed. This product is registered under clinical trial identifier NCT03038594. Target conditions include Burns, Growth Hormone Treatment.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03038594 | Phase 2/3 | Completed |
Competing Products
12 competing products in Burns
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R-Pdf/Gbb 0.01% gel | Johnson & Johnson | Phase 2 | 52 |
| Ceftolozane/tazobactam | Merck | Approved | 85 |
| linezolid | Pfizer | Phase 1 | 32 |
| Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867) | Bayer | Phase 3 | 74 |
| cP12 | United Therapeutics | Phase 2 | 49 |
| cNP8 | United Therapeutics | Phase 1 | 30 |
| Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications | Viatris | Approved | 82 |
| Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin | Baxter | Phase 1/2 | 38 |
| I-020502 | Baxter | Phase 2 | 49 |
| Pathogen-Reduced Plasma + Crystalloid Solutions | Cerus | Approved | 77 |
| NexoBrid + Gel Vehicle | MediWound | Phase 3 | 69 |
| NexoBrid | MediWound | Phase 3 | 69 |